Clinical Observation of Treatment for Advanced Colorectal Cancer with S-1 Plus Oxaliplatin

LONG Jie-ran,HE Jianping,ZHU Wen-yan,LIU Ji-yan,YI Cheng,LUO De-yun,BI Feng,XU Feng

2012-01-01

Abstract:Objective To evaluate the efficacy and safety of the combination of S-1 and oxaliplatin(SOX) in treating advanced colorectal cancer.Methods Between May and December 2011,30 patients were enrolled in this study.S-1 40 mg/m 2 was orally administered twice daily at the following doses on the basis of body surface area(BSA): BSA < 1.25 m 2, 40 mg;1.25 ≤ BSA < 1.50,50 mg;BSA ≥ 1.50,60 mg for 14 days,which was followed by a 7-day rest.Oxaliplatin 130 mg/m 2 was administered(i.v.) on day 1.The regimen was repeated every 3 weeks.The Response Evaluation Criteria in Solid Tumors guidelines were used to evaluate tumor responses,and the National Cancer Institute—Common Toxicity Criteria(version 3.0) were used to assess toxicity after two cycles of treatment,and response evaluable criteria solid tumors(RECIST) was used to evaluate the efficacy.Results In the 30 patients,there were one complete response(3.3%),7 partial responses(23.3%),12 cases of stable disease(40%) and 10 cases of progression(33.3%).The most common toxic effects were hematologic toxicity,gastrointestinal toxicity,cutaneous pigmentation and peripheral neurotoxicity.Among them, 1 patient had grade Ⅳ bone marrow depression,3 had grade Ⅲ anemia,2 had grade Ⅲ diarrhea,2 had grade Ⅲ cutaneous pigmentation,2 had grade Ⅲ nausea and vomiting.The rest of patients had grade Ⅰ or Ⅱ adverse events.Conclusion These data indicate the SOX regimen is effective and well tolerated in patients with advanced coloreactal cancer.